Impact News +++ AST SpaceMobile Rockets 20%, Planet Labs Soars 15%, Rocket Lab Climbs 6% as SpaceX IPO Lifts the Whole... (24/7 Wall St.) +++ AST SPACEMOBILE Aktie +3,05%

IMMUNIC Aktie

>IMMUNIC Performance

1 Woche: +39,2%

1 Monat: +1,0%

3 Monate: +1,0%

6 Monate: +1,0%

1 Jahr: +1,0%

laufendes Jahr: +2,0%

>IMMUNIC Aktie

Name:

IMMUNIC INC. DL-,0001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US4525EP1011 / A2PHD4

Symbol/ Ticker:

10VA (Frankfurt) / IMUX (NASDAQ)

Kürzel:

FRA:10VA, ETR:10VA, 10VA:GR, NASDAQ:IMUX

Index:

Webseite:

https://www.immunic-thera..

Profil:

Immunic Inc. is a late-stage biotechnology company developing a pipeline of selective oral immunology therapies for chronic inflammatory and autoimmune diseases, with a focus on neurologic and gastrointestinal conditions. Its lead program, vidofludim..
>Volltext..

Marktkapitalisierung:

153.21 Mio. EUR

Unternehmenswert:

-7.28 Mio. EUR

Umsatz:

EBITDA:

-94.36 Mio. EUR

Nettogewinn:

-89.88 Mio. EUR

Gewinn je Aktie:

-5.2 EUR

Schulden:

0.36 Mio. EUR

Liquide Mittel:

160.85 Mio. EUR

Operativer Cashflow:

Bargeldquote:

4.86

Umsatzwachstum:

Gewinnwachstum:

-8.19%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

IMMUNIC

Letzte Datenerhebung:

26.05.26

>IMMUNIC Kennzahlen

Aktien/ Unternehmen:

Aktien: 13.62 Mio. St.

Frei handelbar: 99.03%

Leerverk. Aktien: 9.81%

Rückkaufquote: -143.01%

Mitarbeiter: 92

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 231.2%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 1.18

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -99.2%

Eigenkaprendite: -142.91%

>IMMUNIC Peer Group

Gesundheit, Multiple Sklerose- Behandlung, Neurologie/ psychische Behandlung/ Schlaganfälle, Autoimmunerkrankungen

>IMMUNIC Chart & Kurs - NASDAQ

>IMMUNIC News

19.05.26 - 14:36	Immunic Therapeutics (GoingPublic)
	Bildnachweis: Thanayut – stock.adobe.com . Der Beitrag Immunic Therapeutics erschien zuerst auf GoingPublic.de....

19.05.26 - 12:33	Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors (PR Newswire)
	– More Than 30 Years of Leadership Experience Across Biopharmaceutical Commercialization – – Played Key Role in the Launch and Commercial Success of Avonex® for Multiple Sclerosis – NEW YORK, May 19, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company......

19.05.26 - 12:33	Corporate News: Immunic AG (EQS)
	Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors...

13.05.26 - 12:42	Immunic GAAP EPS of -$1.08 misses by $0.12 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.05.26 - 12:33	Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
	– Appointed Globally Renowned Biopharmaceutical Executive and Neurology Drug Developer, Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer – – Continued to Execute Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis, with Top-Line Data Expected by End of......

13.05.26 - 12:33	Corporate News: Immunic AG (EQS)
	Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update...

30.04.26 - 12:36	Immunic to Participate in Investor and Medical Conferences in May (PR Newswire)
	NEW YORK, April 30, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor and medical conferences in May: May 4-6 and 12-13:......

30.04.26 - 12:36	Corporate News: Immunic AG (EQS)
	Immunic to Participate in Investor and Medical Conferences in May...

28.04.26 - 12:33	Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer (PR Newswire)
	– Proven Leader in Neurology Drug Development, Including for Several Approved Multiple Sclerosis Therapies – – Strong Experience in Advancing Late-Stage Clinical Programs and Obtaining Global Regulatory Approvals, Key to Supporting Vidofludimus Calcium Through Pivotal Development – NEW......

28.04.26 - 12:33	Corporate News: Immunic AG (EQS)
	Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer...

24.04.26 - 20:31

XFRA: Deletion of Instruments from Boerse Frankfurt - 24.04.2026 (XETRA)

The following instruments on Boerse Frankfurt do have their last trading day on 24.04.2026. Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 24.04.2026. ISIN Name CA46658Y1034 J2 METALS INC. O.N. CA82967M1005 SIRONA BIOCHEM CORP. FR0013258399 BALYO S.A. EO -,08 NO0010405640 PCI BIOTECH ASA NK 0,03 US4525EP1011 IMMUNIC INC. DL-,0001 ZAE000337051 AFRICA BITCOIN CORP. LTD....

24.04.26 - 16:57	XFRA: ISIN Change (XETRA)
	Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen ZAE000337051 AFRICA BITCOIN CORPORATION LTD. 24.04.2026 ZAE000358925 AFRICA BITCOIN CORPORATION LTD. 27.04.2026 Tausch 1:3 US4525EP1011 Immunic Inc. 24.04.2026 US4525EP2001 Immunic Inc. 27.04.2026 Tausch 10:1 CA46658Y1034 J2 Metals Inc. 24.04.2026 CA4809311042 J2 Metals Inc. 27.04.2026 Tausch 1:1...

24.04.26 - 15:00	Small cap wrap: Trust Stamp, Immunic, Delivra Health Brands, Purepoint Uranium… (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

23.04.26 - 15:09	Immunic announces 1-for-10 reverse stock split (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

23.04.26 - 14:03	Corporate News: Immunic AG (EQS)
	Immunic, Inc. Announces 1-for-10 Reverse Stock Split...

17.04.26 - 21:00

Immunic′s Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says (Benzinga)

Stifel initiates coverage on Immunic (IMUX) with a Buy rating. Analysts see potential for VidoCa to disrupt the MS market via better safety. Latest Ratings for IMUX DateFirmActionFromTo Sep 2021HC Wainwright & Co.MaintainsBuy Apr 2021Aegis CapitalInitiates Coverage OnBuy Mar 2021JMP SecuritiesInitiates Coverage OnMarket Outperform View More Analyst Ratings for IMUX View the Latest Analyst Ratings Importance Rank: 1 read more...

09.04.26 - 12:33	Immunic to Participate in Scientific and Medical Conferences in April (PR Newswire)
	NEW YORK, April 9, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following scientific and medical conferences in April: April 14-16: 8th......

09.04.26 - 12:33	Corporate News: Immunic AG (EQS)
	Immunic to Participate in Scientific and Medical Conferences in April...

07.04.26 - 20:12	Immunic COO highlights the importance of science-led innovation to mark World Health Day (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

01.04.26 - 14:09	Immunic regains compliance with Nasdaq minimum bid price requirement (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer am meisten weiß, glaubt am wenigsten. - Sprichwort Italien

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram